Title : A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.

Pub. Date : 2011 Dec

PMID : 21953275






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. AZD 6244 mitogen-activated protein kinase kinase 1 Homo sapiens